Actively Recruiting
Exploring Clinical Characteristics of Liver Disease Patients Based on Digestive Metabolic Exhaled Air
Led by Shanghai Zhongshan Hospital · Updated on 2025-05-13
1000
Participants Needed
3
Research Sites
195 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cirrhosis is a common digestive system disease and represents the final stage of the progression of various chronic liver diseases. During cirrhosis, the intestinal microenvironment is affected due to liver damage and increased portal venous pressure. Displacement of gut microbiota is closely related to the occurrence and development of cirrhosis. Disruption of the gut microbiota is associated with changes in the levels of nitric oxide (NO), hydrogen (H₂), methane (CH₄), and hydrogen sulfide (H₂S). Breath testing is an emerging method for assessing gut microbiota. This project aims to investigate the characteristics and prognosis of patients with chronic liver disease by detecting exhaled breath markers such as nitric oxide (NO), hydrogen (H₂), methane (CH₄), and hydrogen sulfide (H₂S), in conjunction with results from serological tests, gut microbiota analysis, and radiomics. The goal is to identify new diagnostic biomarkers and therapeutic targets, to recognize high-risk patients at an early stage, and to improve patient survival rates and quality of life.
CONDITIONS
Official Title
Exploring Clinical Characteristics of Liver Disease Patients Based on Digestive Metabolic Exhaled Air
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with chronic liver disease or cirrhosis through liver biopsy pathology or clinical laboratory and imaging examinations
- Undergo molecular breath testing within one week of admission
You will not qualify if you...
- Patients who have received antibiotic treatment within one month
- Patients with severe pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), asthma, or lung malignancies that have not been clinically cured
- Patients who are unable to successfully complete the molecular breath test
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Shanghai Geriatrics Medical Center
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
2
Shanghai Minhang District Central Hospital
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
3
Zhongshan Hospital
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
Research Team
Y
Yiting Wang, Ph.D.
CONTACT
X
Xiaoquan Huang, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here